Sign in

Stefan Oh

Chief Investment Officer at American Healthcare REIT
Executive

About Stefan Oh

Stefan K.L. Oh, 54, is Chief Investment Officer (CIO) of American Healthcare REIT (AHR) since March 2023; previously EVP, Head of Acquisitions (Oct 2021–Mar 2023), EVP of Acquisitions (Oct 2015–Oct 2021), and SVP of Acquisitions (Jan 2015–Oct 2015) at AHR and related Griffin-American entities; earlier roles include acquisitions leadership at Grubb & Ellis–sponsored vehicles, and positions at Healthpeak (formerly HCP) and Ernst & Young. He holds a B.S. in Accounting from Pepperdine University and is a California CPA (inactive) . In 2024, AHR delivered 17.7% Same-Store NOI growth, Normalized FFO of $1.41/share, and improved Net Debt/Adjusted EBITDA from 8.5x to 4.3x as management executed portfolio optimization, deleveraging, and equity raises; the 2024 short-term incentive plan used objective metrics (NFFO/share, Net Debt/Adj EBITDA, Same-Store NOI growth) which all paid at maximum . From listing on Feb 9, 2024 to Dec 31, 2024, AHR’s cumulative TSR measured by an initial $100 stake equaled $226.64 (company) versus $140.07 for its disclosed peer group (company-level context) .

Past Roles

OrganizationRoleYearsStrategic impact
American Healthcare REITChief Investment OfficerMar 2023–presentLeads investments/asset management; drove portfolio dispositions, SHOP/ISHC growth, and capital recycling .
AHREVP, Head of AcquisitionsOct 2021–Mar 2023Led sourcing/execution of acquisitions pipeline .
AHREVP of AcquisitionsOct 2015–Oct 2021Oversaw healthcare real estate acquisitions across platforms .
AHRSVP of AcquisitionsJan 2015–Oct 2015Senior acquisition leadership at AHR .
GAHR III/II, AHI Group Holdings (affiliates)SVP/EVP Acquisitions2009–2021Led acquisitions at Griffin-American vehicles and sponsor affiliates .
Grubb & Ellis–sponsored entitiesLed healthcare real estate acquisitions2007–2012Platform build-out for healthcare acquisitions .
Healthpeak (HCP)Corporate rolesPre-2007Public REIT experience in healthcare real estate .
Ernst & Young LLPProfessional servicesPre-2007Financial/accounting foundation (CPA) .

External Roles

  • None disclosed (no current public company board seats or outside directorships listed for Stefan Oh) .

Fixed Compensation

Metric20232024
Base Salary ($)400,000 425,000
Annual Bonus Opportunity (as % of base)Threshold 37.5%; Target 75%; Max 112.5% Threshold 37.5%; Target 75%; Max 112.5%

2024 STIP structure: 70% corporate (objective) and 30% individual (subjective) for all NEOs; corporate metrics and hurdles are shown below .

Performance Compensation

  • 2024 Short-Term Incentive (STIP) payout (Stefan Oh): $430,313, representing 135% of target; individual component paid at target; corporate metrics all at maximum .

  • 2024 Long-Term Incentive (LTI) mix: 50% time-based RSUs and 50% performance-based RSUs (shifted from 25% performance in 2023 to 50% in 2024), with performance RSUs based on 3-year relative TSR vs a healthcare REIT peer set; time-based RSUs vest ratably over 3 years; TSR PSUs cliff-vest in Q1 2027 subject to outcomes (50%–200% of target) .

  • One-time Listing Equity Award (Feb 9, 2024): additional restricted shares vesting ratably over 4 years recognizing the NYSE listing and capital raises .

2024 Equity Grants (awarded)Shares/UnitsGrant-date value ($)
Time-Based RSUs (Mar 25, 2024)27,454 400,005
Performance-Based RSUs (TSR, target) (Mar 25, 2024)27,454 400,005
Listing Equity Award – Restricted Stock (Feb 9, 2024)74,074 971,851
  • 2022–2024 LTIP cycle (MFFO vs peers): earned 1,904 PSUs for Stefan (86.44% of target performance result); vested in Q1 2025 .

2024 STIP Corporate Metrics and Outcomes (Company-level)

Metric (weight)Threshold (50%)Target (100%)Maximum (150%)Actual 2024Payout result
Normalized FFO per Share (34%)$1.19 $1.22 $1.25 $1.41 Maximum
Net Debt / Adjusted EBITDA (33%)6.5x 6.2x 5.9x 4.3x Maximum
Same-Store NOI Growth (33%)5.5% 6.5% 7.5% 17.7% Maximum

Role-Specific 2024 Achievements (qualitative drivers)

  • Led strategic property dispositions (~$151M gross proceeds), improved portfolio quality, preserved mezzanine investment through loan assumption, and expanded portfolio via ~$139M SHOP and OM investments; strengthened operator relationships and risk management .

Equity Ownership & Alignment

Ownership detailAmount
Beneficially Owned Common Shares (3/27/2025)99,531
Unvested Stock Awards (time-based and certain performance awards), units (12/31/2024)109,802; MV $3,120,573 at $28.42
Unearned Performance Awards outstanding, units (12/31/2024)56,500; MV $1,605,730
2024 Time-Based RSUs outstanding (granted 3/25/24)27,454; vests ratably 2025–2027
2024 TSR PSUs at target (granted 3/25/24)27,454; cliff in Q1 2027 (50%–200% payout)
2024 Listing Restricted Stock74,074; vests 2025–2028
Shares pledged as collateralNone (company disclosure)

Additional alignment policies:

  • Hedging and pledging prohibited for directors and executive officers (Insider Trading Policy) .
  • Clawback policy adopted in connection with NYSE listing standards/SEC Rule 10D-1 .
  • Stock ownership guidelines exist for directors/officers (minimums set in Corporate Governance Guidelines), but specific multiples are not disclosed in the proxy .

Vesting calendar and potential liquidity windows:

  • Annual vest dates: 2/9 (Listing awards, 2025–2028) and 3/25 (time-based RSUs, 2025–2027); Q1 2027 potential PSU vesting based on TSR outcomes; prior 2022–2024 PSUs vested Q1 2025 .

Employment Terms

ScenarioKey economics (CIO)
Termination without Cause or Resignation for Good ReasonCash severance = 1.5x (base salary + 3-year average cash bonus), paid in installments; company COBRA-equivalent coverage during severance period; time-based equity accelerates by 12 months; performance awards eligible to be earned pro-rata based on actual performance .
Change in Control (CIC) without terminationTime-based awards vest immediately prior to CIC; performance awards vest based on actual performance if not assumed/continued .
CIC + termination without Cause / for Good Reason (within 12 months)Cash severance = 2.0x (base salary + 3-year average cash bonus), paid lump sum; COBRA-equivalent coverage during severance period; for performance awards that were assumed, pro-rata vesting based on actual performance at end of performance period .
Death/Disability0.5x base salary; pro-rata annual bonus; 12-month acceleration for time-based awards; performance awards eligible pro-rata based on actual performance .

Illustrative 12/31/2024 table values for Stefan Oh:

  • Severance (no cause/good reason): $1,205,056 cash; medical $42,883; accelerated time-based equity $876,871; continued/accelerated performance awards $337,050 .
  • CIC+termination: $1,606,742 cash; medical $57,178; accelerated time-based equity $3,066,461; performance awards $337,050 (assumed target for calculation) .

Governance protections:

  • No excise tax gross-ups; adherence to clawback; prohibition on hedging/pledging; compensation plans administered by independent Compensation Committee .

Fixed Compensation (detail)

Component2024 amount
Salary$425,000
Bonus (individual/discretionary portion per Summary Comp Table)$95,625
Non-Equity Incentive Plan Compensation (formulaic)$334,688
Stock Awards (grant-date fair value, incl. Listing Equity)$1,771,861
All Other Compensation (401(k) + distributions on awards)$112,041
Total$2,739,215

Note: 2024 totals elevated by one-time Listing Equity Awards granted upon NYSE listing .

Performance Compensation (metric table)

MetricWeightTarget design2024 actual
Normalized FFO/share34%$1.22 target; $1.25 max $1.41 (max)
Net Debt/Adjusted EBITDA33%6.2x target; 5.9x max (lower is better) 4.3x (max)
Same-Store NOI Growth33%6.5% target; 7.5% max 17.7% (max)

Say-on-Pay and Peer Benchmarking

  • Say-on-pay approval: 97.4% support at 2024 annual meeting (for 2023 compensation program) .
  • 2024 compensation peer group disclosed across healthcare and select REITs; TSR-based PSUs in 2024 use a healthcare REIT peer set (CareTrust, HR, LTC, NHI, Healthpeak, Sabra, Omega, Ventas, Welltower) .

Risk Indicators & Red Flags

  • No hedging/pledging (policy) and no shares pledged; no option repricing authority without shareholder approval; no 280G/409A gross-ups; robust clawback policy; lock-ups around 2024 offerings expired (Aug 5, 2024; Nov 17, 2024) .
  • Related-party transaction oversight via formal policy; no specific adverse findings noted related to Stefan Oh in the proxy .

Investment Implications

  • Alignment: Higher weighting of performance-based RSUs (50%) tied to 3-year relative TSR, plus objective STIP metrics (NFFO/share, leverage, and Same-Store NOI) that paid at maximum in 2024, indicate strong pay-for-performance linkage to shareholder outcomes and balance sheet quality .
  • Retention and potential supply of insider shares: Multi-year vesting cadence (annual 2/9 and 3/25 tranches; TSR PSUs in Q1 2027) promotes retention but may create episodic insider selling windows around vest dates; hedging/pledging prohibited and clawback in place mitigate misalignment risk .
  • Severance economics: CIO severance multiples (1.5x; CIC 2.0x) are within market norms and avoid single-trigger cash severance, limiting change-in-control “golden parachute” risk while preserving retention value .
  • Execution track record: Oh’s leadership in dispositions (~$151M), portfolio upgrades, and sourcing off-market SHOP/ISHC opportunities supports underwriting discipline and growth with operator alignment; this complements company-level improvements in leverage and organic NOI growth that drove incentive outperformance in 2024 .
  • Governance and shareholder support: Strong 2024 say-on-pay outcome (97.4%) and prohibition on hedging/pledging reduce governance red flags; no pledging disclosed .